BD teams evaluating China-origin assets understand that NMPA approval is not FDA or EMA approval. What gets underestimated, consistently, is
Bridging NMPA to FDA and EMA: What It Actually Takes to Move a China-Approved Asset West Read More »
In May 2026, the European Parliament and Council reached provisional agreement on the Critical Medicines Act. Most of the coverage
What the EU’s Critical Medicines Act Actually Means for Pharma BD Teams Read More »
Something shifted in China-to-West licensing between 2024 and 2025, and the numbers are stark enough to be worth taking seriously.
How China-Origin Assets Actually Reach EU and US Markets: What the Deal Data Shows Read More »
SEQOVA Biotech Insights | May 2026 The approved CAR-T therapies that reshaped haematological oncology over the past decade were all
Beyond Autologous: Why China’s Allogeneic CAR-T Pipeline Deserves European Attention Now Read More »
You can usually tell where a deal is going to get difficult. Not at the beginning. That part usually moves
Why Good Assets Don’t Close: The Hidden Weight of Execution Read More »
Radiopharmaceuticals innovation in 2026 have moved decisively beyond their historical niche in nuclear medicine. What was once a specialised diagnostic
Interest in long-acting injectables (LAIs) for Central Nervous System (CNS) disorders has returned to business development and investment discussions for
LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026 Read More »
For years, inhalation drug licensing has been misunderstood. It wasn’t deprioritized because it failed scientifically. It was deprioritized because the
Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning Read More »
Computerized System Validation (CSV) is no longer a static compliance exercise. In 2025, regulators made that clear. Both the EMA
